IceCure Medical Ltd
ICCMHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeIceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the. The $4.7M market capitalization puts ICCM squarely in micro-cap range for its industry. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Market Cap
$4.7M
Beta
0.43
P/E (TTM)
—
P/E (Fwd)
-0.31
EPS (TTM)
$-6.91
EPS (Fwd)
$-3.31
ROE
-228.3%
ROA
-73.9%
Cash
$12.0M
Total Debt
$90,000
Free CF
-$9.5M
52W Change
-95.8%
Annual Financials
Cash vs Debt
Where ICCM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ICCM finished 80.11% below its 150-day moving average ($5.43) and 87.71% below its 200-day moving average ($8.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ICCM overbought or oversold?
At the October 20, 2026 close, ICCM's RSI(14) was 19.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $12.0M in cash comfortably exceeding the $90K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$9.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -228.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $3.1M (2022) to $3.4M (2025).
ICCM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, ICCM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ICCM.